Health
Opinion Article
INVITED EDITOR
Editorial from
Lígia Ernesto
Pharmacist | Affiliate Member at Nova SBE Health Economics & Management KC
November 16, 2022
3. Good health and well-being

3. Good health and well-being

Ensuring access to quality health and promoting well-being for all, at all ages
LEARN MORE

Over one century of Pharmaceutical Innovation - Incremental Innovation and Strategic repositioning of acetylsalicylic acid (ASA).

Not just only for your common headache! This century old product has an exciting story to tell about reinvention and staying relevant in today’s pharma market.

Introduced more than 120 years ago, acetylsalicylic acid (ASA) is still today one of Bayer’s best-selling products (1). This success can be attributed to the continuous searching for incremental product innovations and strategic repositioning into new markets.

Over the product’s long history, the continuous investment on diverse incremental technological innovations (see Fig.1) has always been present. This effort promoted the resilience of the product in face of competition contributing to its solid market position (which remains nowadays).

Fig. 1:Innovations/strategic repositioning of ASA over the years versus Global salesof ASA (€ million). Ongoing research with ASA. Sources: (1), (2), (3), (4),(5), (6), (7), (8), (9)

The product has been improved throughout the years, for instance by reducing side effects, facilitating the ease of use, or being repositioned for new indications (see Fig.1).

ASA has been launched in 1901, in its classical tablet form, being one of the first medicines to be marketed in this dosage form (5) facilitating the dosage of the drug and reducing the risk for consumers (4). More than a century of continuous improvements and innovation leadership have followed. Those efforts have been translated in competitive advantages recognized by the consumers and were determinant to the long-lasting sustainability of the product. One example is the chewable ASA tablet that enabled to use the product where no water is available.

The repositioning of the product in 1993 to address new indications for heart attack prevention was an important move, with the Cardio segment representing today almost 40% of Aspirin sales (10). This move also opened the door to the appearance of other antiplatelets (e.g. Clopidogrel in 1998).

ASA was one of the first commonly used drugs and it is still one of the most researched drugs in the world, with an estimated 700 to 1,000 clinical trials conducted each year (11). Future new therapeutic indications might be for cancer prevention or bipolar disorder (7; 8; 9).

The successful history of ASA shows the importance to keep investing in technology to strengthen the brands combined with a strategic repositioning into new markets/indications based on a continuous attention to the insights coming from research and innovation efforts.

References

1. Bayer. Annual Reports. 1998-2018.

2. American Society of Hematology. Antiplatelet Therapy. [Online] 1 December 2008. [Cited: 13 June 2022.] https://www.hematology.org/about/history/50-years/antiplatelet-therapy.

3. Mundo das Marcas. Aspirina. [Online] 30 June 2015. [Cited: 9 June 2022.] https://mundodasmarcas.blogspot.com/2006/05/aspirina-always-for-you-there.html.

4. Jennewein, Klaus. Intellectual Property Management. The Role of Technology-Brands in the Appropriation of Technological Innovation. s.l. : Springer, 2005.

5. Bayer. Aspirin™ - Surprisingly Versatile. [Online] 12 April 2022. [Cited: 13 June 2022.] https://www.bayer.com/en/products/aspirin.

6. The progress in the research of antiplatelet agents (1995–2017). Benimana, Oscar, et al. 10, Future Medicinal Chemistry, Vol. 9, pp. 1087-1110.

7. Aspirin might reduce the incidence of breast cancer: an updated meta-analysis of 38 observational studies. Cao, Yueqing and Tan, Aihua. 38, 2020, Medicine, Vol. 99.

8. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Burn, John, Sheth, Harsh and Elliott, Faye. 10240, 2020, The Lancet, Vol. 395, pp. 1855-1863.

9. NIH U.S. National Library of Medicine. Effects of Low Dose Aspirin in Bipolar Disorder (The A-Bipolar RCT). ClinicalTrials.gov. [Online] 5 September 2021. [Cited: 13 June 2022.] https://clinicaltrials.gov/ct2/show/NCT05035316.

10. When brands complement patents in securing the returns from technological innovation: The case of Bayer Aspirin. Klaus, Jennewein, Durand, Thomas and Gerybadze, Alexander. 3, 2010, Management international/Gestiòn Internacional/International Management, Vol. 14, pp. 73-86.

11. A history of aspirin. Connelly, Dawn. 26 September 2014, The Pharmaceutical Journal. The Official Journal of the Royal Pharmaceutical Society.

Lígia Ernesto
Pharmacist | Affiliate Member at Nova SBE Health Economics & Management KC
LEARN MORE
SHARE

Keep reading

Retirement age: One size does not fit all

The European population is ageing, challenging both the financial and social sustainability of pension systems. By 2050, Portugal will face one of the most alarming scenarios, with roughly two people aged 65 or more for every three at working age — almost doubling the 2016 figure. Reforms in the health system and the labor market are of utmost importance to ensure our pension system remains financially and socially stable throughout the ageing process of our society.

The economics of mental health: from risk factors to financing

In her PhD thesis, Maria Ana Matias investigates the economics of mental health focusing on three dimensions: financing and services organisation, medication adherence, and socio-economic determinants.

Coronavirus pandemic

A European study on the coronavirus and the use of information by the population, involving Iryna Sabat (PhD student) and Pedro Pita Barros, KC Health Economics & Management Scientific Director.

Health Literacy — The Value of Good, Timely, Evidence-based Information

In a life-threatening disease for which a cure is not yet discovered, knowledge about the most promising treatments and how to access them can be determinant for a patient’s life.

THE CHOICES OF

Peak performance: Kilimanjaro leadership quest

In September 2023, Nova School of Business and Economics (Nova SBE) made history as 16 faculty and staff members embarked on an extraordinary journey — the Kilimanjaro Leadership Quest. This ambitious project saw the team conquer Africa's highest peak, Mount Kilimanjaro, imparting invaluable leadership, teamwork, and sustainability lessons.

Subscribe our weekly newsletter

By subscribing to the Nova SBE Role to Play newsletter, you can stay up-to-date on the latest articles posted on the website.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

We all have a role to play

We are on a mission to be a community dedicated to the development of talent and knowledge that impacts the world.

With just ten years to go, an ambitious global effort is underway to deliver the 2030 promise. We want to take a stand and we are calling on our community to showcase how they are contributing to the 17 Sustainable Development Goals, whilst influencing more and more people to unravel their role to play.

Here, you will find four different ways your ideas can flourish, dialogue can be enhanced, and action can take place. You can choose one or all four, and Nova SBE will be there to support you all the way and guarantee tangible change.

We all have a role to play, and this is your way in.